Keros Therapeutics (KROS) Operating Leases (2019 - 2025)
Keros Therapeutics (KROS) posted Operating Leases of $14.5 million for Q4 2025, down 4.21% on a QoQ basis from $15.1 million in Q3 2025, and down 14.26% year-over-year from $16.9 million in Q4 2024.
Keros Therapeutics (KROS) Operating Leases (2019 - 2025) Analysis & Trends
Keros Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $14.5 million for Q4 2025.
- Quarterly Operating Leases fell 14.26% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 14.26% YoY) and the FY2025 annual result came in at $14.5 million, down 14.26% from the prior year.
- Operating Leases was $14.5 million for Q4 2025 at Keros Therapeutics, down from $15.1 million in the prior quarter.
- Across five years, Operating Leases topped out at $17.4 million in Q3 2024 and bottomed at $231000.0 in Q4 2021.
- A 5-year average of $10.5 million and a median of $13.4 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2021 — Operating Leases tumbled 65.03% — and 2022, when it surged 5484.42%.
- Keros Therapeutics' Operating Leases stood at $231000.0 in 2021, then jumped by 5484.42% to $12.9 million in 2022, then rose by 4.18% to $13.4 million in 2023, then grew by 25.63% to $16.9 million in 2024, then retreated by 14.26% to $14.5 million in 2025.
- Business Quant data shows KROS's Operating Leases at $14.5 million in Q4 2025, $15.1 million in Q3 2025, and $15.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.48 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | 15.72 Mn |
| Mar 31, 2025 | 16.31 Mn |
| Dec 31, 2024 | 16.88 Mn |
| Sep 30, 2024 | 17.43 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Mar 31, 2024 | 13.15 Mn |
| Dec 31, 2023 | 13.44 Mn |
| Sep 30, 2023 | 13.70 Mn |
| Jun 30, 2023 | 13.95 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Dec 31, 2021 | 231,000.00 |
| Sep 30, 2021 | 700,000.00 |
| Jun 30, 2021 | 242,000.00 |
| Mar 31, 2021 | 361,000.00 |
| Dec 31, 2020 | 476,000.00 |
| Sep 30, 2020 | 586,000.00 |
| Jun 30, 2020 | 692,000.00 |